Conexeu Sciences Inc. Common Stock (CNXU) - Total Liabilities
Based on the latest financial reports, Conexeu Sciences Inc. Common Stock (CNXU) has total liabilities worth $1.00 Million USD as of April 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Conexeu Sciences Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Conexeu Sciences Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Conexeu Sciences Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See CNXU FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Conexeu Sciences Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Conexeu Sciences Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hites S.A.
SN:HITES
|
Chile | CL$299.48 Billion |
|
STIF Société anonyme
PA:ALSTI
|
France | €24.97 Million |
|
Swelect Energy Systems Limited
NSE:SWELECTES
|
India | Rs-9.54 Billion |
|
Ruentex Materials Co Ltd
TW:8463
|
Taiwan | NT$6.94 Billion |
|
Vranken-Pommery Monopole Société Anonyme
PA:VRAP
|
France | €927.49 Million |
|
Akfen Yenilenebilir Enerji A.S.
IS:AKFYE
|
Turkey | TL16.84 Billion |
|
Tsang Yow Industrial Co Ltd
TW:1568
|
Taiwan | NT$353.63 Million |
|
Tah Kong Chemical Industrial
TWO:4706
|
Taiwan | NT$132.58 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Conexeu Sciences Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CNXU total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Conexeu Sciences Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Conexeu Sciences Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Conexeu Sciences Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-10-31 | $336.02K | -23.45% |
| 2024-10-31 | $438.98K | -- |
About Conexeu Sciences Inc. Common Stock
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, b… Read more